Month: September 2015

Andarix Selected to Present at Prominent Drug Development Conferences

Sep 10, 2015

—

by

cadams

in Article

lung cancer, oncology, orphan drug, pancreatic cancer, personalized medicine, radiotherapy, sclc, targeted therapy

ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at two upcoming conferences in Boston, MA this fall. Both conferences are invitation only for presenting companies, and showcase leading drug development organizations working to advance groundbreaking…